结构-活动关系的数据集成阐明,以合理设计基于化二二烯的素键供体催化剂
Masayuki Kato1,2, Fumio Nakashima1,2, Naoya Ohtsuka1,2
1Institute for Molecular Science, Okazaki, Aichi 444-8787, Japan.
The Journal of organic chemistry
|January 29, 2026
概括
本研究引入了一个数据驱动的框架来预测有机催化剂性能. 它揭示了催化剂结构和电子性质,如吉布斯自由能量和结合常量,是素键 (XB) 催化中的关键活性.
科学领域:
- 机体催化剂是有机催化剂.
- 计算化学计算化学
- 机器学习 机器学习
背景情况:
- 从结构和电子数据中预测催化剂性能是有机催化剂的一个主要挑战.
- 素键 (XB) 捐赠催化剂在各种化学转化中至关重要.
研究的目的:
- 开发一个结合实验,计算和机器学习 (ML) 方法的数据集成框架.
- 为了阐明基于 perfluoroiodoarene 的 XB 供体催化剂的结构-活性关系.
- 确定催化活性的关键决定因素和控制XB供体催化过程的电子因素.
主要方法:
- 单晶X射线衍射和化物结合分析.
- 密度函数理论 (DFT) 的计算.
- 机器学习 (ML) 回归分析集结晶体和电子描述符.
- 沙普利添加剂解释 (SHAP) 分析.
主要成果:
- 含有链接剂的两点XB供体比一点供体具有更强的结合和更高的催化活性.
- 吉布斯自由能量变化 (ΔG) 和结合常数 (K) 被确定为活动的主要决定因素.
- 作为额外的电子因素,强调了 σ/π 孔潜力和核友性 (N 值).
结论:
- 综合实验计算ML方法量化提取XB供体催化剂的关键电子因素.
- 这一框架为扩展非共价相互作用驱动器官催化提供了一个物理可解释的模型.
- 这种方法适用于超出XB形成的和石化键供体系统.
相关概念视频
Structure-Activity Relationships and Drug Design
1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
Local Anesthetics: Chemistry and Structure-Activity Relationship
6.6K
Local anesthetics (LAs) are drugs that induce a temporary loss of sensation in a limited body area, preventing pain. Cocaine was the first local anesthetic discovered in the late 19th century. Cocaine is a benzoic acid ester obtained from the leaves of coca shrubs and was often used for its psychotropic effects. Cocaine was first isolated in 1860 by Albert Niemann. Sigmund Freud studied the physiological actions of cocaine. Carl Koller later introduced it into clinical practice in 1884 as a...
6.6K
Covalent Bonding and Lewis Structures
61.3K
Compared to ionic bonds, which results from the transfer of electrons between metallic and nonmetallic atoms, covalent bonds result from the mutual attraction of atoms for a “shared” pair of electrons.
61.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.8K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Peptide Bonds
82.8K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.8K


